Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H28N2O5S |
Molecular Weight | 432.533 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCC[C@H](N1C(=O)[C@H](CC3=CC=CC=C23)NC(=O)[C@@H](SC(C)=O)C(C)C)C(O)=O
InChI
InChIKey=FXKFFTMLFPWYFH-RDGPPVDQSA-N
InChI=1S/C22H28N2O5S/c1-12(2)19(30-13(3)25)20(26)23-16-11-14-7-4-5-8-15(14)17-9-6-10-18(22(28)29)24(17)21(16)27/h4-5,7-8,12,16-19H,6,9-11H2,1-3H3,(H,23,26)(H,28,29)/t16-,17+,18-,19-/m0/s1
Molecular Formula | C22H28N2O5S |
Molecular Weight | 432.533 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ilepatril, previously known as AVE7688, an inhibitor of neutral endopeptidase and angiotensin-converting enzyme (ACE), was initially being developed for cardiac failure. Ilepatril was in phase IIb/III clinical trials for hypertension and in phase II trials for diabetic nephropathy, however, studies were discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension. | 2006 |
|
Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. | 2011 Jan 15 |
|
Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats. | 2012 Feb 29 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00284128
oral administration (capsules)(2.5 or 10 or 35 or 50 mg ) once daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:13:20 GMT 2023
by
admin
on
Fri Dec 15 17:13:20 GMT 2023
|
Record UNII |
5N1YAP5FCM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB06604
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
5N1YAP5FCM
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
DTXSID7047356
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
9824131
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
300000034188
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
473289-62-2
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
C87731
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY | |||
|
8766
Created by
admin on Fri Dec 15 17:13:20 GMT 2023 , Edited by admin on Fri Dec 15 17:13:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |